Novartis expects bolt-on M&A in India, girds for glivec patent case
This article was originally published in Scrip
Executive Summary
Novartis India will not look at 'big bang' acquisitions on the domestic market but will focus on strategic purchases of branded products, though the current high valuations are a dampener.